Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

AnaptysBio (ANAB) stock in plain English

Free brief · no signupStart here
ANABPublished Nov 14, 2026
AnaptysBio Inc
Healthcare · Biotechnology
Develops antibody drugs to treat severe inflammatory diseases, focusing on immune cell receptors.
Assets:
SHM platformAntibody generation engine based on mammalian somatic hypermutation
San Diego facilitiesHeadquarters and research laboratories located in California
GSK royalty streamQuarterly royalties collected from sales of cancer drug Jemperli
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

85
OPS ScoreOperating finances
Latest quote
+0.72%$47.40
$1.41B
7.9×
$191.47M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 14, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was ANAB. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does AnaptysBio (ANAB) do?

AnaptysBio Inc (ANAB) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Develops antibody drugs to treat severe inflammatory diseases, focusing on immune cell receptors. Develops therapeutic antibodies using laboratory somatic hypermutation technology to target severe inflammatory and. It is worth $1.41B on the market and sold $191.47M over the last year.

Market cap
$1.41B
P/E ratio
7.9×
Annual sales
$191.47M
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 14, 2026

ANAB’s flags, in plain English

Each flag is a number from AnaptysBio’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 14, 2026.

Stupid Cash

Can pay this year's bills 8.4 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Wide Gross Margin

Gross margin of 120% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Capital Works Hard

Earns 65.7% a year on the money it invests in the business. The money in the business, from shareholders and lenders together, earns a strong return. That points to a company that picks its investments well.

Profit with Caveats

Bottom-line profit of $184M in the 12 months to Sep 30, 2026, next to $119M of profit from the business. Bottom-line profit is well above what the business itself earned. The difference came from outside day-to-day operations, such as an investment gain, a tax benefit, the sale of a business or interest on its cash. Some of these may not repeat, and they make the P/E look lower than the business alone would.

2 more green flags and 2 more risk notes open with the free trial. Try it free for 7 days.

Questions about ANAB

How big is AnaptysBio?

AnaptysBio’s market cap is $1.41B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $191.47M: what customers paid the company over the last year, before any costs.

What is ANAB’s P/E ratio?

ANAB’s P/E ratio is 7.9×. Investors pay about 7.9 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with ANAB?

Operating revenue relies substantially on royalty payments from a single partner rather than direct product sales. That is one risk on AnaptysBio’s card. Its first risk flag is Profit with Caveats, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From AnaptysBio’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. ANAB’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card